Pfizer Inc
1PFE
Company Profile
Business description
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Contact
66 Hudson Boulevard East
New YorkNY10001-2192
USAT: +1 212 733-2323
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
81,000
Stocks News & Analysis
stocks
Ask the analyst: Are Qantas shares a value trap?
Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?
stocks
Palantir earnings: Blockbuster growth amid high expectations
We raise our fair value estimate off the back of earnings.
stocks
ResMed earnings: Solid showing from ASX healthcare winner
Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,078.20 | 49.40 | 0.55% |
| CAC 40 | 7,621.04 | 10.97 | -0.14% |
| DAX 40 | 23,846.07 | 88.38 | 0.37% |
| Dow JONES (US) | 44,111.74 | 61.90 | -0.14% |
| FTSE 100 | 9,142.73 | 14.43 | 0.16% |
| HKSE | 24,905.39 | 2.86 | 0.01% |
| NASDAQ | 20,916.55 | 137.03 | -0.65% |
| Nikkei 225 | 40,655.37 | 105.83 | 0.26% |
| NZX 50 Index | 12,888.01 | 10.97 | 0.09% |
| S&P 500 | 6,299.19 | 30.75 | -0.49% |
| S&P/ASX 200 | 8,812.60 | 42.20 | 0.48% |
| SSE Composite Index | 3,619.66 | 2.06 | 0.06% |